Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.
about
RNase H activity: structure, specificity, and function in reverse transcriptionFrom the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-FestinavirHIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT InhibitorsStructural Maturation of HIV-1 Reverse Transcriptase-A Metamorphic Solution to Genomic InstabilityShould we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testingN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceConservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patientsZidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptaseVinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activityCombinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutationsStructure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions.N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors.The "Connection" Between HIV Drug Resistance and RNase HPhenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excisionConnection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimensThe evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.Revisiting plus-strand DNA synthesis in retroviruses and long terminal repeat retrotransposons: dynamics of enzyme: substrate interactions.Clinical management of HIV drug resistance.Mechanisms and factors that influence high frequency retroviral recombinationThe Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.Dual-reporter phenotypic assay for human immunodeficiency virusesAmino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitorsEffect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTAntiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.AZT resistance alters enzymatic properties and creates an ATP-binding site in SFVmac reverse transcriptase.Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment.Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy
P2860
Q24643032-95A73C2B-964A-479C-9A61-DC34EDAFDDC2Q27010583-B1CC14EC-D4CD-425D-A9A1-3CE1B0C54BD4Q27670634-6725C739-BEF9-4638-826F-EBAFD82C3709Q28074527-A16C5DF2-E8E4-4F70-98CE-17CFDBA8C3C3Q28471687-FB610463-7E0F-41D6-B1BF-9518E3D0AF24Q28471689-34DB7CBA-850F-45A1-BF19-973428F6C5E4Q28472255-5C6277A8-92E5-4761-AE00-7C44639F68B6Q28481004-A7758993-0B5B-4820-B7B2-D4D0E086AAA0Q33373484-89ECB8AF-4C48-404F-BF34-9E86A075BCF2Q33535654-D7C7614B-135F-4527-9F47-5F34CB44EAB6Q33826904-8109210A-818D-4634-BFFC-513676A005E2Q33867773-B1C8B152-C8CF-4D0E-8CF9-2FF101C34CC4Q33896402-88A72791-E15F-468C-BA14-6260EF2EA891Q34092798-9010F7E5-E171-49AE-9B8E-B5FCB3B2BFA5Q34094395-A03ECFC4-1EBF-40EA-BB76-7DA12642A7C7Q34223771-E6A9866F-45D4-4E0D-9F02-5FC74ED79403Q34313605-20535AD3-4063-41BA-98BA-FBD28B70D1DDQ34681252-C7465A65-3BA0-4070-92F3-18DE62BDD8C3Q34802871-0FA31684-BE91-4646-9E24-0EB52CFD16E2Q35004847-217F8654-DEAD-443F-9404-D48C68230835Q35042225-AAD84597-DFBE-49AE-97F0-5B9838697067Q35259898-6E8D851F-FD7A-440F-8ADF-E531EECE53C3Q35261045-4063E35E-4F8E-499B-B001-7844757B8482Q35276750-99ABF72E-0424-4726-8754-E058CF033176Q36077418-4F9137D5-3FC2-4E7B-82AC-50566C15FC03Q36347325-EFCFFB61-A307-464D-8309-D1A1C65B31FBQ36452419-F8C97B3F-6576-4056-AA58-20C036590EF0Q36498272-8EF0C758-90B9-46EB-8CE0-4A5C25FAB421Q36553113-91BA2D0F-C501-48AF-A3F2-D351176DF7BBQ36900010-45D2C9E2-A38A-4480-B8F0-4F048A73F790Q37189622-A78C4A2A-5C09-40C8-8743-55C41E362688Q37333826-9C4987DC-451A-4888-AFFB-A92A137D6CA9Q37470030-C0FA4A7F-9FD0-4E36-ACC2-329FDE442B40Q39664167-00ED384B-15DA-417D-9920-9A0DA744A919Q39912641-034FB973-C9B9-4981-BC25-74CF8643A15EQ41879018-649A1CC4-11E0-4852-B5C3-D107F2C3032FQ42152706-8B590B78-70EB-4B78-9F8F-C4625B76B3D3Q42164431-786ADE97-D978-4C7E-B7DA-B5B6754737D2Q42170864-46C3AA56-FC87-4216-BDDD-71FCA4EB60CFQ42430831-9A0C4672-730A-4CB7-838F-9B2CC20D67FC
P2860
Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mutations in human immunodefic ...... -3'-deoxythymidine resistance.
@ast
Mutations in human immunodefic ...... -3'-deoxythymidine resistance.
@en
type
label
Mutations in human immunodefic ...... -3'-deoxythymidine resistance.
@ast
Mutations in human immunodefic ...... -3'-deoxythymidine resistance.
@en
prefLabel
Mutations in human immunodefic ...... -3'-deoxythymidine resistance.
@ast
Mutations in human immunodefic ...... -3'-deoxythymidine resistance.
@en
P2093
P2860
P356
P1433
P1476
Mutations in human immunodefic ...... -3'-deoxythymidine resistance.
@en
P2093
Galina N Nikolenko
Krista A Delviks-Frankenberry
Rebekah Barr
Vinay K Pathak
P2860
P304
P356
10.1128/JVI.02820-06
P407
P577
2007-04-11T00:00:00Z